CA2527191A1 - Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent - Google Patents

Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent Download PDF

Info

Publication number
CA2527191A1
CA2527191A1 CA002527191A CA2527191A CA2527191A1 CA 2527191 A1 CA2527191 A1 CA 2527191A1 CA 002527191 A CA002527191 A CA 002527191A CA 2527191 A CA2527191 A CA 2527191A CA 2527191 A1 CA2527191 A1 CA 2527191A1
Authority
CA
Canada
Prior art keywords
cancer
combination according
group
ingredient
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002527191A
Other languages
English (en)
French (fr)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002634765A priority Critical patent/CA2634765A1/en
Priority to CA002634709A priority patent/CA2634709A1/en
Priority to CA002634766A priority patent/CA2634766A1/en
Publication of CA2527191A1 publication Critical patent/CA2527191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CA002527191A 2003-05-26 2004-05-26 Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent Abandoned CA2527191A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002634765A CA2634765A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634709A CA2634709A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634766A CA2634766A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-148073 2003-05-26
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CA002634709A Division CA2634709A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634766A Division CA2634766A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634765A Division CA2634765A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
CA2527191A1 true CA2527191A1 (en) 2004-12-02

Family

ID=33475383

Family Applications (4)

Application Number Title Priority Date Filing Date
CA002527191A Abandoned CA2527191A1 (en) 2003-05-26 2004-05-26 Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent
CA002634709A Abandoned CA2634709A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634766A Abandoned CA2634766A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634765A Abandoned CA2634765A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA002634709A Abandoned CA2634709A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634766A Abandoned CA2634766A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
CA002634765A Abandoned CA2634765A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (enExample)
EP (1) EP1626719A1 (enExample)
JP (1) JP2006526031A (enExample)
KR (1) KR100938712B1 (enExample)
CN (2) CN1794991A (enExample)
AR (1) AR045318A1 (enExample)
AU (1) AU2004241873C1 (enExample)
BR (1) BRPI0410959A (enExample)
CA (4) CA2527191A1 (enExample)
CL (1) CL2004001278A1 (enExample)
CO (1) CO5660262A2 (enExample)
CR (1) CR8163A (enExample)
CU (1) CU23490B7 (enExample)
EC (1) ECSP056253A (enExample)
IL (1) IL171941A0 (enExample)
ME (1) MEP32308A (enExample)
MX (1) MXPA05012345A (enExample)
NO (1) NO20055417L (enExample)
NZ (1) NZ543591A (enExample)
PE (1) PE20050206A1 (enExample)
RS (1) RS20050884A (enExample)
RU (1) RU2322971C2 (enExample)
TW (1) TW200505424A (enExample)
UA (1) UA81499C2 (enExample)
UY (1) UY28330A1 (enExample)
WO (1) WO2004103369A1 (enExample)
ZA (1) ZA200509515B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008533053A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
DK2010168T3 (da) 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
RS52164B (sr) * 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
WO2010125462A2 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CA2763786C (en) * 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
BR112012004149A2 (pt) * 2009-08-25 2016-03-22 Abraxis Bioscience Llc terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
PT1115391E (pt) * 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
IL149363A0 (en) * 1999-11-10 2002-11-10 Warner Lambert Co Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
ZA200509515B (en) 2006-07-26
NO20055417L (no) 2005-12-19
RU2005140570A (ru) 2006-06-10
KR20060009371A (ko) 2006-01-31
TW200505424A (en) 2005-02-16
JP2006526031A (ja) 2006-11-16
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
RU2322971C2 (ru) 2008-04-27
US20070098816A1 (en) 2007-05-03
AU2004241873B8 (en) 2008-05-29
MEP32308A (en) 2010-10-10
EP1626719A1 (en) 2006-02-22
CA2634709A1 (en) 2004-12-02
ECSP056253A (es) 2006-10-25
RS20050884A (sr) 2008-04-04
NO20055417D0 (no) 2005-11-16
CU23490B7 (es) 2010-02-23
AR045318A1 (es) 2005-10-26
AU2004241873A1 (en) 2004-12-02
AU2004241873B2 (en) 2008-05-08
BRPI0410959A (pt) 2006-07-04
MXPA05012345A (es) 2006-02-08
CO5660262A2 (es) 2006-07-31
KR100938712B1 (ko) 2010-01-25
CL2004001278A1 (es) 2005-05-06
CN1794991A (zh) 2006-06-28
UA81499C2 (en) 2008-01-10
NZ543591A (en) 2009-09-25
IL171941A0 (en) 2006-04-10
WO2004103369A1 (en) 2004-12-02
AU2004241873C1 (en) 2009-01-22
UY28330A1 (es) 2004-12-31
CA2634765A1 (en) 2004-12-02
CA2634766A1 (en) 2004-12-02
PE20050206A1 (es) 2005-03-26

Similar Documents

Publication Publication Date Title
AU2004241873C1 (en) Pharmaceutical composition containing histone deacetylase inhibitor
JPH10279482A (ja) ピリミジン誘導体の単独で又は他の治療方法と組み合わせた癌の予防のための使用
CN102753176B (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
KR20140096375A (ko) 항종양제의 효과 증강제
KR20110025178A (ko) Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
JP7183371B2 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
JP2023505687A (ja) 癌の処置方法
SA04250273B1 (ar) تركيبة صيدلانية تحتوي على مثبط إنزيم الهستوت دي أسيتيليز
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
EP2117539B1 (en) A method of administering an antitumor compound
WO2020045461A1 (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤
US20080275071A1 (en) Radiotherapy Enhancer
US20060128762A1 (en) Medicinal composition and method for treating malignant tumor and utilization thereof
HK40038916A (en) Antitumor agent, antitumor effect potentiator and antitumor kit
EP2174930A1 (en) Antitumor agent comprising sulfostin and sulfostin-related compound as the active ingredient
HK1177889B (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued